For Immediate Release
Chicago, IL – August 17, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (
AMZN Quick Quote AMZN - Free Report) , Amgen Inc. ( AMGN Quick Quote AMGN - Free Report) , TOTAL SE ( TOT Quick Quote TOT - Free Report) , Vertex Pharmaceuticals Incorporated ( VRTX Quick Quote VRTX - Free Report) and FedEx Corporation ( FDX Quick Quote FDX - Free Report) . Here are highlights from Friday’s Analyst Blog: Top Research Reports for Amazon, Amgen and TOTAL
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Amgen and TOTAL. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>> Amazon shares have outperformed the S&P 500 in the year-to-date period (+69.5% vs. +4.6%), with the pandemic accelerating digitization trends that had already been in place. The company has been a leader in both online sales as well as cloud computing and both of those businesses have been thriving during the pandemic.
Moreover, the surge in online grocery shopping was a major positive. Additionally, solid Prime momentum owing to ultrafast delivery services and expanding content portfolio remained tailwind.
Further, strengthening AWS services and its growing adoption rate contributed well. Additionally, improving Alexa skills and features remained a major positive. Expanding smart home products offerings were tailwinds. However, accelerating coronavirus related expenses remain major concerns. Also, foreign exchange headwinds and rising cloud competition are risks.
) read the full research report on Amazon here >>>
Amgen have gained +7% over the past six months against the Zacks Biomedical and Genetics industry’s rise of +2.5%. The Zacks analyst believes that while Amgen’s drugs like Prolia, Evenity, Repatha, Aimovig, Otezla and biosimilars are driving sales, increasing competition for its legacy products continue to hurt the same.
Amgen beat Q2 estimates for earnings and sales. Sales of in-office administration products were hurt by COVID-19 related business disruption, which subsided later in Q2. Amgen boasts a strong biosimilars portfolio, which can drive long-term growth.
Amgen is also progressing with its pipeline while regularly pursuing “external opportunities” such as the acquisition of Otezla and the stake in China's BeiGene. Amgen also expects several important clinical data readouts from its innovative pipeline in the second half of 2020. However, pricing and competitive pressure are concerns.
) read the full research report on Amgen here >>> TOTAL shares have gained +20% over the past three months against the Zacks Integrated International Oil industry’s rise of +6.4%. The Zacks analyst believes that the company is gaining from project startups, renewable assets, LNG portfolio and expanding upstream portfolio that has above industry-average exposure to faster-growing hydrocarbon producing regions.
TOTAL implemented cost-saving measures for preserving liquidity. Streamlining its portfolio and syncing it with long-term objectives are likely to strengthen operations. However, the company’s profitability can be adversely impacted by the ongoing decline in commodity prices.
It remains exposed to acquisition-related risk as these assets contribute a sizable volume to production. TOTAL's operations in some politically-troubled regions and increasing competition might affect profitability.
) read the full research report on TOTAL here >>>
Other noteworthy reports we are featuring today include Vertex Pharmaceuticals and FedEx.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q2 2020, while the S&P 500 gained an impressive +44.0%, five of our strategies returned +50.9%, +93.8%, +122.2%, +153.0%, and even +156.8%.
This outperformance has not just been a recent phenomenon. From 2000 – Q2 2020, while the S&P averaged +5.5% per year, our top strategies averaged up to +51.7% per year.
See their latest picks free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.